Currently Viewing:
Supplements Treatment Strategies for Dyslipidemia
Introduction
Rising to the Challenge of Treating High-risk Patients
Robert M. Guthrie, MD
Cost Efficiency and Formulary Considerations for Statin Therapy
Terrance Killilea, PharmD; and Lori Funk, PharmD
An Assessment of Statin Safety
James M. McKenney, PharmD
Cost Efficiency and Formulary Considerations for Statin Therapy
Terrance Killilea, PharmD; and Lori Funk, PharmD
An Assessment of Statin Safety
James M. McKenney, PharmD
Rising to the Challenge of Treating High-risk Patients
Robert M. Guthrie, MD
Participating Faculty
Introduction
Currently Reading
Participating Faculty

Participating Faculty

This second part of a 3-part supplement series to The American Journal of Managed Care addresses various clinical and economic aspects of statin therapy in treating dyslipidemia.

Faculty
Lori Funk, PharmD
Clinical Pharmacist
Cape Fear Valley Health System
Highsmith-Rainey Memorial Hospital
Fayetteville, North Carolina

Robert M. Guthrie, MD
Professor
College of Medicine and Public Health
Ohio State University
Columbus, Ohio

Terrance Killilea, PharmD
Vice President of Pharmacy
Regence Blue Shield of Idaho
Boise, Idaho

James M. McKenney, PharmD
Professor Emeritus
Virginia Commonwealth University
President and Chief Executive Officer
National Clinical Research, Inc
Richmond, Virginia

Disclosure Statement

It is the policy of The American Journal of Managed Care to have all faculty who participate in programs sponsored by pharmaceutical organizations disclose any real or apparent conflicts of interest.

These participants report relationships with the following pharmaceutical companies:

  • Robert M. Guthrie, MD
      Grant/Research support from:
        Abbott Laboratories Boehringer Ingelheim Bristol-Myers Squibb GlaxoSmithKline
      Consultant for:
      • AstraZeneca
      Speaker's bureau/Honorarium:
      • AstraZeneca
  • James M. McKenney, PharmD
      Speaker's honoraria from:
      • AstraZeneca
      • KOS
      • Merck/Schering-Plough
      • Pfizer
      • Reliant
      Research grant support from:
      • AstraZeneca
      • GlaxoSmithKline
      • KOS
      • Merck
      • Pfizer
      • Roche (research grant to National Clinical Research, Inc)
      • Schering-Plough
      • Takeda
      Consulting services provided for:
      • AstraZeneca
      • KOS
      • Microbia
      • Pfizer
      • Sankyo

The following participants have declared no financial affiliations with corporate organizations:

  • Lori Funk, PharmD
  • Terrance Killilea, PharmD

We would like to thank Wayne Kuznar for editorial assistance in the development of two of these articles (as noted in footnotes).

Signed disclosures are on file at the office of The American Journal of Managed Care, Princeton, New Jersey.

Funding

This publication was made possible by a grant from AstraZeneca.


---

The contents of this supplement may include information regarding the use of products that may be inconsistent outside the approved labeling for these products in the United States. Physicians should note that the use of these products outside current approved labeling is considered experimental and are advised to consult prescribing information for these products.

PDF
 
Copyright AJMC 2006-2019 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome the the new and improved AJMC.com, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up